Last reviewed · How we verify
De-escalation strategy
De-escalation strategy refers to a clinical approach of reducing drug dose, frequency, or intensity of treatment based on patient response or risk assessment.
At a glance
| Generic name | De-escalation strategy |
|---|---|
| Also known as | Ticagrelor 60 mg, aspirin early discontinuation |
| Sponsor | Dong-A University |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
De-escalation is a therapeutic strategy rather than a specific drug, involving stepwise reduction of antimicrobial agents, chemotherapy, or other medications after initial treatment response or based on biomarker-guided decisions. This approach aims to minimize cumulative toxicity, reduce adverse effects, and lower treatment burden while maintaining clinical efficacy.
Approved indications
Common side effects
Key clinical trials
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Managing Aggression: Effectiveness of Model-Based Standardized Patient Simulation (NA)
- Multidisciplinary Low-Barrier and Mobile HIV Care to Improve Retention and Viral Suppression: Stakeholder-Engaged Design and Evaluation (NA)
- De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma (PHASE2)
- Circulating Tumor DNA Response In Urothelial Cancer (PHASE2)
- Promoting Socioemotional Development in Early Childhood: Implementation and Evaluation of the VIPP-SD Parenting Intervention in Portugal (NA)
- Trauma Intervention to Optimize PrEP Among Women Who Inject Drugs (NA)
- Step-down Therapy After Long-term Osteoporosis Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |